Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review

被引:2
|
作者
Ahmad, Zeeshanuddin [1 ]
Jain, Amar [1 ]
Mehta, Nikhil [1 ]
Saldanha, Elroy [1 ]
Patel, Dhruv [1 ]
Desai, Sanjay M. [1 ]
机构
[1] Sri Aurobindo Med Coll & Post Grad Inst, Dept Surg Oncol, Indore, Madhya Pradesh, India
关键词
Epithelial ovarian cancer (EOC); Primary cytoreductive surgery (PCS); Interval debulking surgery (IDS); Neoadjuvant chemotherapy (NACT); ADVANCED-STAGE OVARIAN; EXPLORATORY ANALYSIS; SURVIVAL; CARCINOMA; TIME;
D O I
10.1007/s40944-018-0253-2
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
ObjectiveTo compare theoverall survival of women with advanced-stage EOC treated by PCS versus NACT followed by IDS.Design, Setting, and ParticipantsRetrospective study of women with stage IIB-IVA ovarian carcinoma FIGO staging diagnosed between 2016 and 2018 treated at Department of Surgical Oncology, Sri Aurobindo Medical College and Post Graduate Institute, Indore.ExposuresInitial treatment approach of PCS versus NACT+IDS, examined using an intent-to-treat analysis.ResultsThe median follow-up was 18months (10-36months) in both groups. The median overall survival was 38months in PCS group and 31months in NACT group. Postoperative complications were seen more often in PCS group (11.3%) against 3.33% in NACT group. Patients with residual disease (microscopic and macroscopic residual disease) had poorer prognosis.ConclusionsPrimary cytoreductive surgery is associated with improved survival compared with NACT in otherwise healthy women with bulky epithelial ovarian. The biggest risk associated with the use of NACT is that patients with significant side effects and refractory disease will lose the opportunity for initial surgery. The lower survival in women receiving NACT can be owed to limited performance status in women undergoing NACT.
引用
下载
收藏
页数:4
相关论文
共 50 条
  • [21] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Ce Bian
    Kui Yao
    Li Li
    Tao Yi
    Xia Zhao
    Archives of Gynecology and Obstetrics, 2016, 293 : 163 - 168
  • [22] Primary Debulking Surgery Versus Neoadjuvant Chemotherapy in Stage IV Ovarian Cancer
    J. Alejandro Rauh-Hain
    Noah Rodriguez
    Whitfield B. Growdon
    A. K. Goodman
    David M. Boruta
    Neil S. Horowitz
    Marcela G. del Carmen
    John O. Schorge
    Annals of Surgical Oncology, 2012, 19 : 959 - 965
  • [23] Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer
    Rauh-Hain, I.
    Growdon, W.
    Rodriguez, N.
    Goodman, A.
    Boruta, D.
    Horowitz, N.
    Del Carmen, M.
    Schorge, J.
    GYNECOLOGIC ONCOLOGY, 2011, 121 (01) : S12 - S13
  • [24] Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer
    Bian, Ce
    Yao, Kui
    Li, Li
    Yi, Tao
    Zhao, Xia
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2016, 293 (01) : 163 - 168
  • [25] Neoadjuvant chemotherapy combined with interval cytoreductive surgery in ovarian cancer
    Du, Xinjie
    Lin, Xiaojie
    JOURNAL OF BUON, 2019, 24 (05): : 2035 - 2040
  • [26] Prognostic role of pathologic response and cytoreductive status at interval debulking surgery after neoadjuvant chemotherapy for advanced epithelial ovarian cancer
    Liang, Margaret I.
    Prendergast, Emily N.
    Staples, Jeanine N.
    Holschneider, Christine H.
    Cohen, Joshua G.
    Cass, Ilana
    JOURNAL OF SURGICAL ONCOLOGY, 2019, 120 (04) : 779 - 785
  • [27] NEOADJUVANT (CYTOREDUCTIVE) CHEMOTHERAPY COMBINED WITH INTERVENTION DEBULKING SURGERY IN ADVANCED, UNRESECTED EPITHELIAL OVARIAN-CANCER
    LAWTON, FG
    REDMAN, CWE
    LUESLEY, DM
    CHAN, KK
    BLACKLEDGE, G
    OBSTETRICS AND GYNECOLOGY, 1989, 73 (01): : 61 - 65
  • [28] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    Alexandre A. B. A. da Costa
    Camila V. Valadares
    Glauco Baiocchi
    Henrique Mantoan
    Augusto Saito
    Solange Sanches
    Andréia P. Guimarães
    Maria Isabel W. Achatz
    Annals of Surgical Oncology, 2015, 22 : 971 - 978
  • [29] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    da Costa, Alexandre A. B. A.
    Valadares, Camila V.
    Baiocchi, Glauco
    Mantoan, Henrique
    Saito, Augusto
    Sanches, Solange
    Guimaraes, Andreia P.
    Achatz, Maria Isabel W.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S971 - S978
  • [30] Should neoadjuvant chemotherapy be preferred to an alternative treatment for advanced ovarian cancer: Comparison of neoadjuvant chemotherapy followed by interval debulking surgery and primary debulking surgery in patients with advanced ovarian cancer
    Liu, J.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 176 - 176